Clover Health Investments enters this week with a striking contradiction: the stock has surged 52% over the past month, yet insiders have been selling into almost every uptick — and short sellers haven't budged.
The stock closed at $2.61 on May 5, down roughly 1.5% on the day and off 1.1% on the week. That slight fade is modest compared to the scale of the recent run-up, but it arrives just as earnings loom — the company is due to report Q1 2026 results on June 10. The tension between a heavily re-rated stock and a persistently skeptical short base is the defining feature of CLOV's setup right now.
Short interest in CLOV remains elevated — and notably sticky. At 9.3% of the free float, shorts have trimmed from a peak of around 10.1% in late March but have refused to exit meaningfully. Over the past month, SI % of FF has fallen roughly 0.8 percentage points. That's orderly covering, not a capitulation. The official FINRA reading — settled mid-April — showed 40.6 million shares short, with days to cover at a substantial 7.67 days. The ORTEX short score of 68 ranks in just the 6th percentile of the universe, flagging this as a name where positioning remains under pressure. Cost to borrow is negligible at 0.45%, having drifted lower from a brief spike above 0.6% in mid-April. Borrow availability is not tight — roughly 55% of borrowed shares remain available for new shorts to enter, well within normal territory. The picture is one of entrenched but unhurried short conviction: bears are taking their time, not their profits.
Options are flashing a mild caution signal, though not an alarm. The put/call ratio has crept to 0.29, about 1.6 standard deviations above its 20-day average of 0.24. That's a step up in defensive hedging — particularly notable given how low the PCR has been running through most of April. The 52-week range for the PCR spans 0.12 to 0.54, so current levels are elevated relative to recent history but nowhere near year-high extremes. What the move captures is a modest shift: call-heavy positioning has been the dominant mode, and the recent uptick in puts suggests some option traders are beginning to protect gains rather than chase them. The RSI at 67 is elevated but not yet overbought. Taken together, the borrow and options data describe a market that is neither squeezing shorts out nor piling into fresh downside — a standoff.
The Street is cautious, and the most recent analyst moves lean that direction. The last firm to act was Canaccord Genuity in late March, trimming its price target from $3.70 to $3.20 while keeping a Buy rating. Before that, Leerink Partners cut its target from $3.00 to $2.50, maintaining Market Perform. Both moves happened before the stock's sharp April rally — meaning the mean consensus target of $2.82 now sits barely above the current price of $2.61, representing only about 8% implied upside. After a 52% one-month move, the Street hasn't caught up. The analyst data carries a staleness flag — the most recent formal consensus update is from mid-March — so treat these targets as a floor of information rather than current guidance. On factor scores, the earnings picture is genuinely interesting: CLOV scores in the 91st percentile on both 90-day EPS momentum and EPS surprise, suggesting the underlying business has been consistently beating expectations. The P/E multiple at 31.3x has expanded 8.6 points over 30 days, tracking the stock's run. EV/EBITDA at 21.9x has compressed slightly over the same period — the two multiples moving in opposite directions as earnings estimates drift higher.
The insider picture is perhaps the most attention-grabbing element this week. Multiple executives sold shares in April, clustered tightly around the April 15 date: the President, divisional CEOs, the Acting CFO, and the General Counsel all registered sales, each at prices in the low-$2.00s. Andrew Toy, the President, made the largest single disposal — 309,558 shares at $1.76 on April 1, then a further 60,765 shares at $2.04 on April 15. Net insider activity over 90 days shows about 1 million shares sold on balance, worth roughly $2.1 million. The transactions all carry low trade significance scores and appear consistent with routine plan-driven selling. But the breadth — six different insiders selling into the same price window — is worth noting as the stock has since run materially higher. CEO Vivek Garipalli remains the dominant holder at 17.9% of shares, with no recent disposal on record.
Among correlated peers, HUM gained 4.3% on the week and HNGE surged 11.2%, while UNH slipped 0.8%. CLOV's own flat-to-negative week sits somewhere in the middle of a divergent healthcare cohort — not giving back the gains, but no longer leading.
The June 10 earnings date is now the focal point. The only earnings reaction on record — last February's Q3 report — saw the stock fall 5.1% the next day and 7.0% over the following week. With the PE multiple near its highest level in months, a strong EPS track record built into the price, and insiders having distributed shares on the way up, the gap between the stock's recent enthusiasm and the Street's still-cautious targets is the tension most worth watching into that print.
See the live data behind this article on ORTEX.
Open CLOV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
